Kopran Limited , a prominent pharmaceutical company, has filed revised disclosures with stock exchanges regarding inter-family share transfers among its promoter group members. The company submitted these corrected filings on December 25, 2025, addressing incomplete details in earlier submissions.

Revised Disclosure Filing

The company received observations from BSE Limited regarding incomplete details in the original disclosures filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The missing information included acquisition dates and equity share capital details. Following communication with the respective promoter group members, Kopran Limited received and submitted revised disclosures.

Key Share Transfer Transactions

The revised disclosures cover multiple inter-family transfers that occurred in September 2025:

Major Acquisitions

Share Disposals

Persons Acting in Concert

The transactions involve several entities acting in concert with the promoter group:

• Oriental Enterprises Partnership Firm (17,64,750 shares - 3.65%)
• Panorama Finvest Private Ltd. (38,00,000 shares - 7.87%)
• Parijat Shipping and Finale Limited (9,11,109 shares - 1.89%)
• Sarvamangal Mercantile Company Ltd. (29,02,951 shares - 6.01%)
• Oricon Enterprises Limited (62,17,183 shares - 12.88%)
• United Shippers Limited (22,00,000 shares - 4.56%)

Transaction Mode and Compliance

All transfers were executed through off-market transactions as inter-family transfers. The transactions remain exempt from open offer requirements under SEBI regulations, and all parties have committed to maintaining compliance with applicable disclosure requirements.

The revised filings provide complete transparency regarding the promoter group's shareholding restructuring, ensuring full regulatory compliance and accurate market disclosure.

Kopran Limited , a pharmaceutical company, has reported a consolidated net loss for the second quarter of fiscal year 2026, as revenue declined year-over-year. The company's financial performance reflects challenges in the current market environment.

Financial Highlights

For the quarter ended September 30, 2025, Kopran reported the following consolidated results:

The company's revenue decreased significantly by 94.80% compared to the same quarter last year. This substantial decline in revenue contributed to a net loss of ₹992.32 lakh, compared to a profit of ₹738.41 lakh in the previous year's corresponding quarter.

Half-Year Performance

For the half-year period, Kopran's consolidated revenue stood at ₹25,312.55 lakh, compared to ₹29,099.84 lakh in the previous year, indicating a year-over-year decline.

Standalone Performance

On a standalone basis, Kopran's revenue for the quarter was ₹4,238.93 lakh, down from ₹7,352.96 lakh in the same quarter last year, representing a decrease of about 42.40%.

Board Approval and Business Operations

The Board of Directors approved these unaudited financial results at their meeting held on November 12, 2025. Kopran primarily operates in the pharmaceuticals business through its group entities.

Conclusion

Kopran's Q2 FY2026 results indicate a period of significant financial challenges for the company, with substantial declines in revenue and a shift from profit to loss. The dramatic decrease in consolidated revenue and the resulting net loss underscore the difficulties faced by the company during this quarter.